Every candidate is evaluated against the actual regulatory and operational context of the role. Our four-step process is built around GxP depth, validation lifecycle experience, and inspection-readiness posture in FDA-regulated manufacturing environments.
We screen for regulatory depth in FDA-regulated operations, GxP validated environment experience, documentation quality, and the ability to operate under inspection pressure.
Before sourcing begins, we define the search against validation lifecycle phase, FDA audit exposure, system criticality, and your GxP regulatory posture. That means a structured conversation about where the role sits in your compliance environment and what qualified looks like given your specific validated systems and regulatory standing. A pharmaceutical manufacturer under active FDA scrutiny requires a different candidate profile than a CDMO building a new program. We scope accordingly.
Candidates are evaluated on their applied experience with the regulatory frameworks relevant to your environment: 21 CFR Parts 11, 210/211, and 820; EU Annex 11; GAMP 5; IQ/OQ/PQ; ICH Q10; and change control under GMP. Through structured conversation, we distinguish candidates who have operated these frameworks under production conditions at regulated manufacturers from those with peripheral exposure. That distinction does not surface on a résumé.
We assess the quality, defensibility, and regulatory rigor of candidates' documentation practices and their direct FDA or notified body audit interaction history. In pharmaceutical and biotech manufacturing, documentation is evidence that FDA investigators may examine. We explore whether candidates produce audit-defensible records under production pressure and probe their direct inspection interaction, including 483 observation response experience.
You receive a concise shortlist aligned to your search criteria. Every submission includes context on the candidate's regulatory background, production system experience, and documentation approach, and a clear explanation of why they fit your manufacturing environment and the specific demands of the role.
GxP manufacturing hiring carries compliance risks that surface only through deep, domain-specific evaluation. The process below reflects how we approach every search in this practice.
Technical aptitude matters. So does understanding what it means to operate within a change-controlled, inspection-ready manufacturing system where documentation quality has patient safety consequences.
Manufacturers under active FDA scrutiny, including warning letters, consent decrees, or pre-approval inspections, operate under fixed remediation timelines with real consequences. We screen with that regulatory urgency in mind.
In pharmaceutical and biotech manufacturing, documentation is evidence that FDA investigators may examine directly. We assess whether candidates produce audit-defensible records under production conditions, not just during pre-inspection preparation.
A pharma validation lead, a biotech CSV specialist, and a CDMO quality systems manager are different searches. Each is scoped against the specific regulatory environment, production system landscape, and compliance posture of the organization.
FDA-regulated manufacturers are inspection-ready at all times, not just during active preparation windows. We look for professionals who operate with that posture as a baseline.
In pharmaceutical, biotech, and medical device manufacturing, validated production systems and quality processes ultimately protect patients. We evaluate candidates against that standard, because that is the standard your manufacturing operation is held to.
Tell us about the role and your GxP manufacturing environment. We'll apply the same rigor to your search that your organization applies to validated production systems.